OA03.04 A Phase 1b Study Of Furmonertinib, an Oral, Brain Penetrant, Selective EGFR Inhibitor, in Patients with Advanced NSCLC with EGFR Exon 20 Insertions

Baohui Han, Changcheng Zhou, Wei Zheng, Li‐Wha Wu, Zhiyuan Ma, Hui Wang, Xianjun Yu, Guowen Ding, Daqing Ma, Lin Nie, Zhe Zhang, Xin Dong, Yuanyuan Shang, Kai Tang, Wenda Zhang, John Hsu, Yajun Jiang, Qi Zhao